Rockley Photonics (NYSE:RKLY) announced today that it agreed to enter a development partnership with Medtronic (NYSE:MDT).
The two companies plan to collaborate to add Rockley’s Bioptx biomarker sensing platform to Medtronic’s offerings for use across a number of healthcare settings.
According to a news release, Rockley designed its biosensing technology to expand the capabilities of wearable medtech devices through the miniaturization of measurement and analysis for an array of biomarkers into a compact form factor.
Rockley’s technology aims to make it so a single wearable device can monitor multiple crucial biomarkers, including core body temperature, blood pressure, body hydration, alcohol, lactate, and glucose trends, among others. The Bioptx platform offers end-to-end sensing that integrates cloud analytics and artificial intelligence (AI) to potentially deliver a holistic assessment of a variety of conditions.
The company said its partnership with Medtronic aims to build on the societal shift from reactive to proactive healthcare by offering round-the-clock, real-time, non-invasive monitoring of a person’s health and wellbeing, giving clinicians the means to personalize care with actionable data.
“This partnership combines Medtronic’s exceptional strength in providing in-patient care with Rockley’s expertise in wearable, remote monitoring,” Rockley Chairperson and CEO Dr. Andrew Rickman said in the release. “I believe that this collaboration will bring to life our vision of giving people better insights into their health and well-being. We are excited about the potential for this partnership to herald the next generation of wearable devices and deliver a complete lifecycle of patient care.”